Get the Stockscreener App
11.65
1.84%
0.21
After Hours:
11.67
0.02
+0.17%
Hutchmed China Limited Adr stock is traded at $11.65, with a volume of 75,005.
It is up +1.84% in the last 24 hours and up +7.18% over the past month.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
See More
Previous Close:
$11.44
Open:
$11.63
24h Volume:
75,005
Relative Volume:
1.61
Market Cap:
$2.00B
Revenue:
$549.97M
Net Income/Loss:
$458.86M
P/E Ratio:
4.4405
EPS:
2.6236
Net Cash Flow:
$-89.06M
1W Performance:
+8.78%
1M Performance:
+7.18%
6M Performance:
-15.27%
1Y Performance:
-26.31%
1-Day Range:
$11.44
$11.81
1-Week Range:
$10.45
$11.81
52-Week Range:
$9.77
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
11.65 | 1.85B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-13-25 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
REGHutchmed China LtdHUTCHMED Announces NMPA Approval for ORPATHYS - TradingView
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
0J7G Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView
Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan
RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire
HUTCHMED analyst targets stay high, shares trade well below consensus - AD HOC NEWS
HUTCHMED Announces Phase III China Data from ESLIM-02 Study of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia - aastocks.com
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewswire Inc.
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in - GlobeNewswire
HUTCHMED (Nasdaq: HCM) files AIM block for 43,616,756 shares - Stock Titan
HCMHUTCHMED (China) Limited ADR Stock Price and Quote - Finviz
HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan
HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com
HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com
New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - GlobeNewswire
HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan
和黃醫藥(00013.HK)索樂匹尼布上市申請獲受理並納入優先審評 - AASTOCKS.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
HUTCHMED (Nasdaq: HCM) launches registrational Phase III HMPL-760 lymphoma trial in China - Stock Titan
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):